Cite

    Ziff, M. et al. (2021). Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set. Leukemia & lymphoma. 62 (5), pp. 1243-1246. [Online].